Accelerated therapeutic progress in diffuse large B cell lymphoma

Qingqing Cai, Jason Westin, Kai Fu, Madhav Desai, Liang Zhang, Huiqiang Huang, Wenqi Jiang, Rong Liang, Zhengzi Qian, Richard E. Champlin, Michael Wang

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in the world. Clinically, biologically, and pathologically, DLBCL is a heterogeneous entity with a range of potential outcomes. Immunochemotherapy regimens, consisting of the chimeric monoclonal anti-CD20 antibody rituximab in combination with chemotherapy, have improved the outcomes. Relapsed DLBCL is generally treated with salvage immunochemotherapy followed by high-dose therapy and autologous stem cell transplantation; however, DLBCL is not yet curable in up to a third of patients. The real promise for cure lies in novel agents and their rational combinations. The improved understanding of DLBCL subtypes and gene expression profiling has led to the identification of targeted drugs that may allow for subtype specific therapy. We have summarized the existing data on the prognostic factors and the treatment of DLBCL, including the use of novel agents such as lenalidomide, carfilzomib, and ibrutinib. We also share our thoughts on the direction of future clinical trials.

Original languageEnglish (US)
Pages (from-to)541-556
Number of pages16
JournalAnnals of Hematology
Volume93
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Therapeutics
Stem Cell Transplantation
Gene Expression Profiling
Combination Drug Therapy
Non-Hodgkin's Lymphoma
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Diffuse large B cell lymphoma
  • Immunochemotherapy
  • Novel biological agents
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Cai, Q., Westin, J., Fu, K., Desai, M., Zhang, L., Huang, H., ... Wang, M. (2014). Accelerated therapeutic progress in diffuse large B cell lymphoma. Annals of Hematology, 93(4), 541-556. https://doi.org/10.1007/s00277-013-1979-7

Accelerated therapeutic progress in diffuse large B cell lymphoma. / Cai, Qingqing; Westin, Jason; Fu, Kai; Desai, Madhav; Zhang, Liang; Huang, Huiqiang; Jiang, Wenqi; Liang, Rong; Qian, Zhengzi; Champlin, Richard E.; Wang, Michael.

In: Annals of Hematology, Vol. 93, No. 4, 01.01.2014, p. 541-556.

Research output: Contribution to journalReview article

Cai, Q, Westin, J, Fu, K, Desai, M, Zhang, L, Huang, H, Jiang, W, Liang, R, Qian, Z, Champlin, RE & Wang, M 2014, 'Accelerated therapeutic progress in diffuse large B cell lymphoma', Annals of Hematology, vol. 93, no. 4, pp. 541-556. https://doi.org/10.1007/s00277-013-1979-7
Cai, Qingqing ; Westin, Jason ; Fu, Kai ; Desai, Madhav ; Zhang, Liang ; Huang, Huiqiang ; Jiang, Wenqi ; Liang, Rong ; Qian, Zhengzi ; Champlin, Richard E. ; Wang, Michael. / Accelerated therapeutic progress in diffuse large B cell lymphoma. In: Annals of Hematology. 2014 ; Vol. 93, No. 4. pp. 541-556.
@article{88902fde930249c58553c7db85461edb,
title = "Accelerated therapeutic progress in diffuse large B cell lymphoma",
abstract = "Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in the world. Clinically, biologically, and pathologically, DLBCL is a heterogeneous entity with a range of potential outcomes. Immunochemotherapy regimens, consisting of the chimeric monoclonal anti-CD20 antibody rituximab in combination with chemotherapy, have improved the outcomes. Relapsed DLBCL is generally treated with salvage immunochemotherapy followed by high-dose therapy and autologous stem cell transplantation; however, DLBCL is not yet curable in up to a third of patients. The real promise for cure lies in novel agents and their rational combinations. The improved understanding of DLBCL subtypes and gene expression profiling has led to the identification of targeted drugs that may allow for subtype specific therapy. We have summarized the existing data on the prognostic factors and the treatment of DLBCL, including the use of novel agents such as lenalidomide, carfilzomib, and ibrutinib. We also share our thoughts on the direction of future clinical trials.",
keywords = "Diffuse large B cell lymphoma, Immunochemotherapy, Novel biological agents, Rituximab",
author = "Qingqing Cai and Jason Westin and Kai Fu and Madhav Desai and Liang Zhang and Huiqiang Huang and Wenqi Jiang and Rong Liang and Zhengzi Qian and Champlin, {Richard E.} and Michael Wang",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00277-013-1979-7",
language = "English (US)",
volume = "93",
pages = "541--556",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Accelerated therapeutic progress in diffuse large B cell lymphoma

AU - Cai, Qingqing

AU - Westin, Jason

AU - Fu, Kai

AU - Desai, Madhav

AU - Zhang, Liang

AU - Huang, Huiqiang

AU - Jiang, Wenqi

AU - Liang, Rong

AU - Qian, Zhengzi

AU - Champlin, Richard E.

AU - Wang, Michael

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in the world. Clinically, biologically, and pathologically, DLBCL is a heterogeneous entity with a range of potential outcomes. Immunochemotherapy regimens, consisting of the chimeric monoclonal anti-CD20 antibody rituximab in combination with chemotherapy, have improved the outcomes. Relapsed DLBCL is generally treated with salvage immunochemotherapy followed by high-dose therapy and autologous stem cell transplantation; however, DLBCL is not yet curable in up to a third of patients. The real promise for cure lies in novel agents and their rational combinations. The improved understanding of DLBCL subtypes and gene expression profiling has led to the identification of targeted drugs that may allow for subtype specific therapy. We have summarized the existing data on the prognostic factors and the treatment of DLBCL, including the use of novel agents such as lenalidomide, carfilzomib, and ibrutinib. We also share our thoughts on the direction of future clinical trials.

AB - Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in the world. Clinically, biologically, and pathologically, DLBCL is a heterogeneous entity with a range of potential outcomes. Immunochemotherapy regimens, consisting of the chimeric monoclonal anti-CD20 antibody rituximab in combination with chemotherapy, have improved the outcomes. Relapsed DLBCL is generally treated with salvage immunochemotherapy followed by high-dose therapy and autologous stem cell transplantation; however, DLBCL is not yet curable in up to a third of patients. The real promise for cure lies in novel agents and their rational combinations. The improved understanding of DLBCL subtypes and gene expression profiling has led to the identification of targeted drugs that may allow for subtype specific therapy. We have summarized the existing data on the prognostic factors and the treatment of DLBCL, including the use of novel agents such as lenalidomide, carfilzomib, and ibrutinib. We also share our thoughts on the direction of future clinical trials.

KW - Diffuse large B cell lymphoma

KW - Immunochemotherapy

KW - Novel biological agents

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84896403797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896403797&partnerID=8YFLogxK

U2 - 10.1007/s00277-013-1979-7

DO - 10.1007/s00277-013-1979-7

M3 - Review article

VL - 93

SP - 541

EP - 556

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 4

ER -